195 related articles for article (PubMed ID: 35454817)
1. Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy.
Tran CG; Borbon LC; Mudd JL; Abusada E; AghaAmiri S; Ghosh SC; Vargas SH; Li G; Beyer GV; McDonough M; Li R; Chan CHF; Walsh SA; Wadas TJ; O'Dorisio T; O'Dorisio MS; Govindan R; Cliften PF; Azhdarinia A; Bellizzi AM; Fields RC; Howe JR; Ear PH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454817
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine carcinoma tumor spheroid drug screen reveals vulnerability to tyrosyl-DNA phosphodiesterase 1 inhibitors.
Beyer GV; Hueser S; Li R; Manika D; Lee M; Chan CHF; Howe JR; Ear PH
Surgery; 2024 Mar; 175(3):605-612. PubMed ID: 37914572
[TBL] [Abstract][Full Text] [Related]
3. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.
Wang Y; Wang W; Jin K; Fang C; Lin Y; Xue L; Feng S; Zhou Z; Shao C; Chen M; Yu X; Chen J
Oncol Lett; 2017 Mar; 13(3):1165-1174. PubMed ID: 28454229
[TBL] [Abstract][Full Text] [Related]
5. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
6. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
10. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
11. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
12. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.
Krieg A; Mersch S; Boeck I; Dizdar L; Weihe E; Hilal Z; Krausch M; Möhlendick B; Topp SA; Piekorz RP; Huckenbeck W; Stoecklein NH; Anlauf M; Knoefel WT
PLoS One; 2014; 9(2):e88713. PubMed ID: 24551139
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Dai M; Mullins CS; Lu L; Alsfasser G; Linnebacher M
World J Gastrointest Surg; 2022 May; 14(5):383-396. PubMed ID: 35734622
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
16. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
17. Establishment and Characterization of a Novel Cell Line Derived from a Small Cell Neuroendocrine Carcinoma of the Anal Canal.
Dizdar L; Drusenheimer J; Werner TA; Möhlendick B; Schütte SC; Esposito I; Filler TJ; Knoefel WT; Krieg A
Neuroendocrinology; 2018; 107(3):246-256. PubMed ID: 30025411
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
19. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T
Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
